



<https://www.nrk.no/rogaland/kan-revolusjonere-slagbehandlingen-1.13459706>

The Company



Founded in 2005


Publicly listed 2012

Strategic partners and sub-contractors
around the world

Sales of research instruments

Support by EU grants





Clot – 85%

Efficient treatment is
available – but timing is
crucial!

Only a few percent
receive accurate
treatment !

Traumatic Brain Injuries (TBI)

- Traffic
- Sports
- Military



The Market



Ambulances



Hospital



Military

the problem addressed



10 million cases of stroke per year worldwide

- 64 Billion € in Europe (800,000 cases)

15 million traumatic brain injuries per year worldwide

- 100 billion € in Europe (1,600,000 cases)

Second position in mortality 2015

Second largest cause of disability

Regional differences include:

- China number 1
- Baltic number 4
- Nordic number 4

Attract only 2% of the global healthcare resources

Market size

around 200 000 ambulances in the world

around 5000 hospitals in the USA

around 6000 acute hospitals in UK, Ger, Fra

around 85 000 hospitals in India and China

Example:

replacing system every five years gives a steady state annual market of 60,000 systems


with 1% (10%) market penetration 600 (6000) systems would be sold each year

the MD100 system has a list price of 100,000\$

this would give annual sales of 60 M\$ (600M\$)



“Time is brain”



1h	2h	3h	4h	4,5h
----	----	----	----	------



Solution:




Partners and customers




South Western Ambulance Service **NHS**
NHS Foundation Trust




The Strokefinder product



The Strokefinder product





Clinical Trials - Summary



Five trials with a total of 454 enrolled subjects

- Two explorative proof of principle trials (MF01, MF02)
- One prospective trial to evaluate detection of physiological changes inside the skull (MF03)
- One prospective trial to evaluate performance, safety and usability in relation to stroke (MF04)
- One trial to evaluate detection of chronic subdural hematoma (CSH01)

Positive primary endpoints in all 5 trials

- MF04 Adequate measurement data for at least 80% of stroke patients
- CSH01 At 100% sensitivity, 70% specificity for detecting subdural hematoma

No safety issues in relation to device or procedure

Clinical Trials – Ongoing and planned



TICH 01 – Prospective multicentre trial to evaluate the ability to detect traumatic intracranial bleeding

VGR 01 – Prospective trial to evaluate the diagnostic ability to differentiate hemorrhagic stroke from ischemic stroke and stroke mimics in the acute phase

Multicentre trial in Norway evaluating stroke diagnosis in pre-hospital and hospital settings starting 2017

Stroke trial in Australia starting 2017


Multicentre trial in UK evaluating head trauma diagnosis in pre-hospital and hospital settings starting 2017



- Increase the inclusion of patients for improvement of qualified data
- Increase the number of studies
- Secure data quality in academic initiated studies
- St George and Kings in London
- South West Ambulance Service Trust (SWAST) (Eurostar) clinical demo with prehospital paramedics





Detection of the bleeding inside the brain (Imaging)



Results from measurement:
BLEEDING
Middle
Left
Down



Thorax diagnostics





efan.blomsterberg@medfielddiagnostics.com
www.medfielddiagnostics.com

